Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials

Shamir R Mehta; William E Boden; John W Eikelboom; Marcus Flather; P Gabriel Steg; Alvaro Avezum; Rizwan Afzal; Leopoldo S Piegas; David P Faxon; Petr Widimsky; Andrzej Budaj; Susan Chrolavicius; Hans-Jurgen Rupprecht; Sanjit Jolly; Christopher B Granger; Keith A A Fox; Jean-Pierre Bassand; Salim Yusuf; OASIS 5 and 6 Investigators

doi:10.1161/CIRCULATIONAHA.108.789479

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials

Shamir R Mehta, William E Boden, John W Eikelboom, Marcus Flather, P Gabriel Steg, Alvaro Avezum, Rizwan Afzal, Leopoldo S Piegas, David P Faxon, Petr Widimsky, Andrzej Budaj, Susan Chrolavicius, Hans-Jurgen Rupprecht, Sanjit Jolly, Christopher B Granger, Keith A A Fox, Jean-Pierre Bassand, Salim Yusuf, OASIS 5 and 6 Investigators

Research output: Contribution to journal › Article › peer-review

93 Citations (Scopus)

Abstract

The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported.

Original language	English
Pages (from-to)	2038-46
Number of pages	9
Journal	Circulation
Volume	118
Issue number	20
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.108.789479
Publication status	Published - 11 Nov 2008

Keywords

Acute Coronary Syndrome
Aged
Angioplasty, Balloon, Coronary
Anticoagulants
Double-Blind Method
Drug Administration Schedule
Electrocardiography
Enoxaparin
Female
Hemorrhage
Heparin
Hospitalization
Humans
Male
Middle Aged
Myocardial Infarction
Polysaccharides
Stroke
Treatment Outcome

Access to Document

10.1161/CIRCULATIONAHA.108.789479

Cite this

Mehta, S. R., Boden, W. E., Eikelboom, J. W., Flather, M., Steg, P. G., Avezum, A., Afzal, R., Piegas, L. S., Faxon, D. P., Widimsky, P., Budaj, A., Chrolavicius, S., Rupprecht, H-J., Jolly, S., Granger, C. B., Fox, K. A. A., Bassand, J-P., Yusuf, S., & OASIS 5 and 6 Investigators (2008). Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation, 118(20), 2038-46. https://doi.org/10.1161/CIRCULATIONAHA.108.789479

Mehta, Shamir R ; Boden, William E ; Eikelboom, John W et al. / Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes : an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. In: Circulation. 2008 ; Vol. 118, No. 20. pp. 2038-46.

@article{4e6380fdca9e43549330ab88ded94fab,

title = "Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials",

abstract = "The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported.",

keywords = "Acute Coronary Syndrome, Aged, Angioplasty, Balloon, Coronary, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Electrocardiography, Enoxaparin, Female, Hemorrhage, Heparin, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Polysaccharides, Stroke, Treatment Outcome",

author = "Mehta, {Shamir R} and Boden, {William E} and Eikelboom, {John W} and Marcus Flather and Steg, {P Gabriel} and Alvaro Avezum and Rizwan Afzal and Piegas, {Leopoldo S} and Faxon, {David P} and Petr Widimsky and Andrzej Budaj and Susan Chrolavicius and Hans-Jurgen Rupprecht and Sanjit Jolly and Granger, {Christopher B} and Fox, {Keith A A} and Jean-Pierre Bassand and Salim Yusuf and {OASIS 5 and 6 Investigators}",

year = "2008",

month = nov,

day = "11",

doi = "10.1161/CIRCULATIONAHA.108.789479",

language = "English",

volume = "118",

pages = "2038--46",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott, Williams and Wilkins",

number = "20",

}

Mehta, SR, Boden, WE, Eikelboom, JW, Flather, M, Steg, PG, Avezum, A, Afzal, R, Piegas, LS, Faxon, DP, Widimsky, P, Budaj, A, Chrolavicius, S, Rupprecht, H-J, Jolly, S, Granger, CB, Fox, KAA, Bassand, J-P, Yusuf, S & OASIS 5 and 6 Investigators 2008, 'Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials', Circulation, vol. 118, no. 20, pp. 2038-46. https://doi.org/10.1161/CIRCULATIONAHA.108.789479

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes : an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. / Mehta, Shamir R; Boden, William E; Eikelboom, John W et al.

In: Circulation, Vol. 118, No. 20, 11.11.2008, p. 2038-46.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes

T2 - an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials

AU - Mehta, Shamir R

AU - Boden, William E

AU - Eikelboom, John W

AU - Flather, Marcus

AU - Steg, P Gabriel

AU - Avezum, Alvaro

AU - Afzal, Rizwan

AU - Piegas, Leopoldo S

AU - Faxon, David P

AU - Widimsky, Petr

AU - Budaj, Andrzej

AU - Chrolavicius, Susan

AU - Rupprecht, Hans-Jurgen

AU - Jolly, Sanjit

AU - Granger, Christopher B

AU - Fox, Keith A A

AU - Bassand, Jean-Pierre

AU - Yusuf, Salim

AU - OASIS 5 and 6 Investigators

PY - 2008/11/11

Y1 - 2008/11/11

N2 - The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported.

AB - The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported.

KW - Acute Coronary Syndrome

KW - Aged

KW - Angioplasty, Balloon, Coronary

KW - Anticoagulants

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Electrocardiography

KW - Enoxaparin

KW - Female

KW - Hemorrhage

KW - Heparin

KW - Hospitalization

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Polysaccharides

KW - Stroke

KW - Treatment Outcome

U2 - 10.1161/CIRCULATIONAHA.108.789479

DO - 10.1161/CIRCULATIONAHA.108.789479

M3 - Article

C2 - 18955665

VL - 118

SP - 2038

EP - 2046

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 20

ER -

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479